Literature DB >> 30778141

Cancer-associated fibroblasts in gastrointestinal cancer.

Hiroki Kobayashi1,2, Atsushi Enomoto3, Susan L Woods1, Alastair D Burt4, Masahide Takahashi2, Daniel L Worthley5.   

Abstract

The tumour microenvironment, also termed the tumour stroma or tumour mesenchyme, includes fibroblasts, immune cells, blood vessels and the extracellular matrix and substantially influences the initiation, growth and dissemination of gastrointestinal cancer. Cancer-associated fibroblasts (CAFs) are one of the critical components of the tumour mesenchyme and not only provide physical support for epithelial cells but also are key functional regulators in cancer, promoting and retarding tumorigenesis in a context-dependent manner. In this Review, we outline the emerging understanding of gastrointestinal CAFs with a particular emphasis on their origin and heterogeneity, as well as their function in cancer cell proliferation, tumour immunity, angiogenesis, extracellular matrix remodelling and drug resistance. Moreover, we discuss the clinical implications of CAFs as biomarkers and potential targets for prevention and treatment of patients with gastrointestinal cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30778141     DOI: 10.1038/s41575-019-0115-0

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  123 in total

Review 1.  Tackling TAMs for Cancer Immunotherapy: It's Nano Time.

Authors:  Yishun Yang; Jianfeng Guo; Leaf Huang
Journal:  Trends Pharmacol Sci       Date:  2020-10       Impact factor: 14.819

2.  Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.

Authors:  Tongtong Wei; Jinjing Song; Kai Liang; Li Li; Xiaoxiang Mo; Zhiguang Huang; Gang Chen; Naiquan Mao; Jie Yang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

Review 3.  Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.

Authors:  Meng Lan; Wenping Lu; Tengteng Zou; Lihong Li; Fengjie Liu; Tiange Cai; Yu Cai
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

Review 4.  The mesenchymal context in inflammation, immunity and cancer.

Authors:  Vasiliki Koliaraki; Alejandro Prados; Marietta Armaka; George Kollias
Journal:  Nat Immunol       Date:  2020-08-03       Impact factor: 25.606

5.  Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit.

Authors:  Bailiang Li; Yuming Jiang; Guoxin Li; George A Fisher; Ruijiang Li
Journal:  JCI Insight       Date:  2020-05-07

6.  Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion.

Authors:  Hailong Liu; Youliang Sun; Jenny A O'Brien; Janusz Franco-Barraza; Xueling Qi; Hongyu Yuan; Wei Jin; Junping Zhang; Chunyu Gu; Zhenyu Zhao; Chunjiang Yu; Shiyu Feng; Xinguang Yu
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

Review 7.  Cancer-associated fibroblasts: overview, progress, challenges, and directions.

Authors:  Qinrong Ping; Ruping Yan; Xin Cheng; Wenju Wang; Yiming Zhong; Zongliu Hou; Yunqiang Shi; Chunhui Wang; Ruhong Li
Journal:  Cancer Gene Ther       Date:  2021-03-12       Impact factor: 5.987

Review 8.  Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy.

Authors:  Wen-Jun Zhang
Journal:  Purinergic Signal       Date:  2021-01-09       Impact factor: 3.765

Review 9.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

10.  Cell-type deconvolution analysis identifies cancer-associated myofibroblast component as a poor prognostic factor in multiple cancer types.

Authors:  Bingrui Li; Guangsheng Pei; Jun Yao; Qingqing Ding; Peilin Jia; Zhongming Zhao
Journal:  Oncogene       Date:  2021-06-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.